scholarly journals Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

2020 ◽  
Vol 88 (3) ◽  
pp. 574-587 ◽  
Author(s):  
David J. Irwin ◽  
Janel Fedler ◽  
Christopher S. Coffey ◽  
Chelsea Caspell‐Garcia ◽  
Ju Hee Kang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Biomarkers ◽  
Early Parkinson’S Disease

scholarly journals Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology

2013 ◽  
Vol 8 ◽  
pp. BMI.S11422 ◽  
Author(s):  
Chera L. Maarouf ◽  
Thomas G. Beach ◽  
Charles H. Adler ◽  
Michael Malek-Ahmadi ◽  
Tyler A. Kokjohn ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Early Stage ◽  
Csf Biomarkers ◽  
Cerebrospinal Fluid Biomarkers ◽  
Proteomic Study ◽  
Quantitative Appraisal

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in postmortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12–1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest coexistent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.

scholarly journals Cerebrospinal Fluid Biomarkers for Kii Amyotrophic Lateral Sclerosis/Parkinsonism-Dementia Complex

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Yui Nakayama ◽  
Satoru Morimoto ◽  
Misao Yoneda ◽  
Shigeki Kuzuhara ◽  
Yasumasa Kokubo
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Enzyme Linked Immunosorbent Assay ◽  
Phosphorylated Tau ◽  
Total Tau ◽  
Lateral Sclerosis

Objective. Amyotrophic lateral sclerosis/parkinsonism-dementia complex is classified as one of the tauopathies. Methods. The total tau, phosphorylated tau, and amyloid β42 levels were assayed in cerebrospinal fluid from patients with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex (), Alzheimer’s disease (), Parkinson’s disease (), amyotrophic lateral sclerosis (), and controls () using specific enzyme-linked immunosorbent assay methods. Results. Total tau and phosphorylated tau did not increase and amyloid β42 was relatively reduced in Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Relatively reduced amyloid β42 might discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from amyotrophic lateral sclerosis and Parkinson’s disease, and the ratios of phosphorylated-tau to amyloid β42 could discriminate Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease. Conclusions. Cerebrospinal fluid analysis may be useful to differentiate amyotrophic lateral sclerosis/parkinsonism-dementia complex from Alzheimer’s disease, amyotrophic lateral sclerosis, and Parkinson’s disease.

Working memory in mild Alzheimer's disease and early Parkinson's disease.

2003 ◽  
Vol 17 (2) ◽  
pp. 230-239 ◽  
Author(s):  
Elizabeth A. Kensinger ◽  
Deirdre K. Shearer ◽  
Joseph J. Locascio ◽  
John H. Growdon ◽  
Suzanne Corkin
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Working Memory ◽  
Parkinson's Disease ◽  
Early Parkinson’S Disease

scholarly journals Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease

2015 ◽  
Vol 21 (7) ◽  
pp. 758-764 ◽  
Author(s):  
Ane Løvli Stav ◽  
Dag Aarsland ◽  
Krisztina Kunszt Johansen ◽  
Erik Hessen ◽  
Eirik Auning ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Amyloid Β ◽  
Cerebrospinal Fluid Biomarkers ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document